Bone Health and Osteoporosis: Causes, Diagnosis, and Evidence-Based Treatment

What Osteoporosis Means

Osteoporosis is a skeletal disorder in which reduced bone strength raises fracture risk. The condition is often silent until a low-trauma fracture occurs, which is why screening and risk assessment matter. DXA reports compare a patient's bone mineral density with a young-adult reference population and express the result as a T-score. A T-score at or below -2.5 is osteoporosis; a T-score between -1.0 and -2.5 is low bone mass, often called osteopenia.

Bone density is only part of the risk picture. Age, prior fracture, parental hip fracture, smoking, alcohol use, glucocorticoids, rheumatoid arthritis, secondary osteoporosis, and femoral-neck BMD can all alter the 10-year probability of hip or major osteoporotic fracture. That is why many guidelines use FRAX or another validated risk tool rather than treating every osteopenia result the same way. The distinction between DXA measures is explained in our T-score versus Z-score guide.

Why Bone Loss Accelerates

Bone is remodeled throughout life by osteoclasts that resorb bone and osteoblasts that form new bone. Estrogen helps restrain osteoclast activity. After menopause, the loss of estrogen signaling shifts remodeling toward resorption, especially in the early postmenopausal years. Khosla, Oursler, and Monroe's 2012 review, "Estrogen and the skeleton," explains the biology of estrogen's effects on bone cells, but it should be used as mechanistic background rather than as a patient-specific treatment rule. [1]

Men can develop osteoporosis too. Aging, hypogonadism, glucocorticoid exposure, low body weight, heavy alcohol use, smoking, malabsorption, chronic kidney disease, and androgen-deprivation therapy can all raise risk. A man with a fragility fracture deserves evaluation even though population-wide screening evidence in men is less settled.

Current Screening Guidance

The 2025 U.S. Preventive Services Task Force recommendation is straightforward for women: screen women 65 years or older, and screen postmenopausal women younger than 65 when clinical risk assessment indicates increased fracture risk. For men, the USPSTF states that evidence is insufficient to assess the balance of benefits and harms of screening to prevent fractures. [2]

That "I statement" for men does not mean clinicians should ignore male fracture risk. It means there is not enough evidence for a universal preventive screening recommendation. Men with prior fragility fracture, long-term glucocorticoid use, hypogonadism, very low body weight, or other major risk factors may still be evaluated with DXA as part of clinical care.

When Medication Is Considered

The Bone Health and Osteoporosis Foundation clinician guide includes fracture-risk thresholds for pharmacologic treatment. Medication is generally considered for adults with hip or vertebral fracture, osteoporosis-range T-score, or low bone mass plus raised 10-year fracture probability. [3] The exact threshold should be applied to the right population and updated clinical context, not copied into a universal self-treatment rule.

Bisphosphonates such as alendronate, risedronate, and zoledronic acid reduce fracture risk for many patients and are often first-line when kidney function and gastrointestinal factors allow. The Fracture Intervention Trial demonstrated vertebral-fracture risk reduction with alendronate in women who already had vertebral fractures. [6] Denosumab also reduced vertebral, nonvertebral, and hip fractures in a large placebo-controlled trial. [7] It should not be stopped without a follow-on plan because rebound-associated vertebral fractures have been reported after discontinuation. [9]

Anabolic options such as teriparatide, abaloparatide, and romosozumab are generally reserved for very high fracture risk or treatment failure. In the ARCH trial, a romosozumab-to-alendronate sequence reduced fracture risk more than alendronate alone, while the cardiovascular safety signal requires attention when selecting patients. [8] Glucocorticoid-induced osteoporosis has its own risk-assessment and treatment pathway because fracture risk can rise rapidly after sustained steroid exposure. [10]

Calcium, Vitamin D, Exercise, and Falls

Nutrition is supportive, not magical. Adults should try to meet calcium needs primarily through food, using supplements only to close the gap when diet is insufficient. Vitamin D intake and testing should be individualized, especially in people with malabsorption, limited sun exposure, kidney disease, or medications that alter vitamin D metabolism. Excess supplementation can cause harm, so more is not automatically better.

Exercise helps preserve strength, posture, and balance. Weight-bearing activity, progressive resistance training, and balance work can reduce fall risk and support bone health. For someone with severe osteoporosis or recent fracture, exercise plans should be modified to avoid high-impact loading and risky spinal flexion until a clinician or physical therapist gives specific guidance.

Hormone Therapy and Testosterone Therapy

Menopausal hormone therapy can prevent bone loss and reduce fracture risk in selected patients, and The Menopause Society's 2022 position statement recognizes bone benefits alongside treatment of vasomotor and genitourinary symptoms. [4] It is not automatically prescribed solely for osteoporosis prevention because breast cancer, endometrial cancer, thromboembolism, stroke, coronary disease, age, time since menopause, and uterine status all matter.

Testosterone therapy increased volumetric bone density and estimated bone strength in a controlled trial of older men with low testosterone, but fracture outcomes were not established. [5] It is not a substitute for osteoporosis therapy when fracture-risk thresholds are met. A man being evaluated for testosterone deficiency should still have fracture risk addressed directly, including DXA when clinically indicated and approved osteoporosis medications when risk is high.

Follow-Up

Monitoring should answer a real clinical question: Is fracture risk falling, is bone density stable, and is the patient tolerating therapy? Repeat DXA is often considered after treatment has had enough time to show an effect, commonly 1 to 2 years in higher-risk situations, but the interval can be longer for low-risk screening follow-up. New fragility fracture, height loss, back pain suggesting vertebral fracture, glucocorticoid initiation, or major medication changes can justify earlier reassessment.

Bottom Line

The safest osteoporosis page does not promise one universal protocol. It helps readers understand who should be screened, how DXA and FRAX fit together, why estrogen biology matters, and why medication decisions belong in a risk-stratified plan. The strongest evidence-based path is to identify fracture risk early, correct reversible contributors, reduce falls, and choose medication according to guideline thresholds and individual contraindications.